In Brief: LocalMed
This article was originally published in The Gray Sheet
Executive Summary
LocalMed: Files investigational device exemption with FDA for its PerfusaSleeve device "which converts an ordinary angioplasty catheter into a perfusion balloon," the company says in a Feb. 8 release. Using the over-the-balloon technology employed in LocalMed's InfusaSleeve drug delivery catheter, cleared via 510(k) in October 1994 ("The Gray Sheet" Oct. 31, 1994, p. 3), PerfusaSleeve "aligns with the balloon and permits blood to flow during angioplasty procedures by routing it around the angioplasty balloon." The blood enters "perfusion channels upstream from the balloon and exits through ports distal to the balloon," LocalMed explains...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.